COMPANY
Blacksmith Medicines
Blacksmith Medicines has received NIH funding, most recently in fiscal 2026 for the project “Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases”. From public records Source · Oct 12, 2026
NIH awards 5
- NIH award 1R43CA309911-01A1 FY2026: $399,915 awarded for that fiscal year; activity R43 (SBIR); PI TAGANOV, KONSTANTIN; recipient as written: BLACKSMITH MEDICINES, INC., SAN DIEGO, CA. Combination of a novel selectiv source ↗
- NIH contract (government contract; not a grant and not an investment round) 75N93022C00060-P00015-9999-1 FY2026: $860,542 awarded for that fiscal year; activity N01 (OTHER_NIH); PI TOMARAS, ANDREW; recipient as written: BLACKSMITH MEDICINES, INC., SAN DIEGO, C source ↗
- NIH contract (government contract; not a grant and not an investment round) 75N93022C00060-P00003-9999-1 FY2024: $6,265,409 awarded for that fiscal year; activity N01 (OTHER_NIH); PI TOMARAS, ANDREW; recipient as written: BLACKSMITH MEDICINES, INC., SAN DIEGO, source ↗
- NIH contract (government contract; not a grant and not an investment round) 75N93022C00060-0-9999-1 FY2022: $4,712,500 awarded for that fiscal year; activity N01 (OTHER_NIH); PI TOMARAS, ANDREW; recipient as written: BLACKSMITH MEDICINES, INC., SAN DIEGO, CA. source ↗
- NIH award 1R43AI120246-01A1 FY2016: $150,000 awarded for that fiscal year; activity R43 (SBIR); PI PUERTA, DAVID; recipient as written: BLACKSMITH MEDICINES, INC., SAN DIEGO, CA. Novel small molecule inhibitors of Lp source ↗
Funding and NIH signals
- NIH award NIH awarded $400K (SBIR Phase I 1R43CA309911-01A1, new, notice Sep 11, 2026). NIH RePORTER 1R43CA309911-01A1 (Sep 11, 2026)
Evidence (1 event)
- Sep 11, 2026 · NIH RePORTER 1R43CA309911-01A1
Organization: BLACKSMITH MEDICINES, INC.; City/State: SAN DIEGO, CA; Project number: 1R43CA309911-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 399915; Administering IC: National Cancer Institute; Project title: Combination of a novel selective FEN1 metallonuclease inhibitor with Olaparib for the treatment of PARP-resistant ovarian cancers; Organization type: Domestic For-Profits
- Sep 11, 2026 · NIH RePORTER 1R43CA309911-01A1
Raises and deals from press releases
- Deal Zoetis deal · amount not disclosed · announced Feb 14, 2024 Company release ↗
Source quote
- Feb 14, 2024 · Company release ↗
“Blacksmith Medicines and Zoetis Announce Research Collaboration for Novel Animal Health Antibiotics”
- Feb 14, 2024 · Company release ↗